495 related articles for article (PubMed ID: 35390032)
21. SARS-CoV-2 induces "cytokine storm" hyperinflammatory responses in RA patients through pyroptosis.
Zheng Q; Lin R; Chen Y; Lv Q; Zhang J; Zhai J; Xu W; Wang W
Front Immunol; 2022; 13():1058884. PubMed ID: 36532040
[TBL] [Abstract][Full Text] [Related]
22. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
Adhami M; Sadeghi B; Rezapour A; Haghdoost AA; MotieGhader H
BMC Biotechnol; 2021 Mar; 21(1):22. PubMed ID: 33711981
[TBL] [Abstract][Full Text] [Related]
23. The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities.
Arisan ED; Dart A; Grant GH; Arisan S; Cuhadaroglu S; Lange S; Uysal-Onganer P
Viruses; 2020 Jun; 12(6):. PubMed ID: 32512929
[TBL] [Abstract][Full Text] [Related]
24. Identification of Novel SARS-CoV-2 Drug Targets by Host MicroRNAs and Transcription Factors Co-regulatory Interaction Network Analysis.
Sardar R; Satish D; Gupta D
Front Genet; 2020; 11():571274. PubMed ID: 33173539
[TBL] [Abstract][Full Text] [Related]
25. Comparative transcriptome analysis of SARS-CoV, MERS-CoV, and SARS-CoV-2 to identify potential pathways for drug repurposing.
Krishnamoorthy P; Raj AS; Roy S; Kumar NS; Kumar H
Comput Biol Med; 2021 Jan; 128():104123. PubMed ID: 33260034
[TBL] [Abstract][Full Text] [Related]
26. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
Fiscon G; Conte F; Farina L; Paci P
PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
[TBL] [Abstract][Full Text] [Related]
27. Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs.
Pierce JB; Simion V; Icli B; Pérez-Cremades D; Cheng HS; Feinberg MW
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33207533
[TBL] [Abstract][Full Text] [Related]
28. Meta-Data Analysis to Explore the Hub of the Hub-Genes That Influence SARS-CoV-2 Infections Highlighting Their Pathogenetic Processes and Drugs Repurposing.
Mosharaf MP; Kibria MK; Hossen MB; Islam MA; Reza MS; Mahumud RA; Alam K; Gow J; Mollah MNH
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016137
[TBL] [Abstract][Full Text] [Related]
29. ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors.
Wicik Z; Eyileten C; Jakubik D; Simões SN; Martins DC; Pavão R; Siller-Matula JM; Postula M
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33233425
[TBL] [Abstract][Full Text] [Related]
30. Exploration of key drug target proteins highlighting their related regulatory molecules, functional pathways and drug candidates associated with delirium: evidence from meta-data analyses.
Mosharaf MP; Alam K; Gow J; Mahumud RA
BMC Geriatr; 2023 Nov; 23(1):767. PubMed ID: 37993790
[TBL] [Abstract][Full Text] [Related]
31. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
32. Blood transcriptome analysis revealed the crosstalk between COVID-19 and HIV.
Yan C; Niu Y; Wang X
Front Immunol; 2022; 13():1008653. PubMed ID: 36389792
[TBL] [Abstract][Full Text] [Related]
33. Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes.
Islam MB; Chowdhury UN; Nain Z; Uddin S; Ahmed MB; Moni MA
Comput Biol Med; 2021 Sep; 136():104668. PubMed ID: 34340124
[TBL] [Abstract][Full Text] [Related]
34. Identification of common molecular signatures of SARS-CoV-2 infection and its influence on acute kidney injury and chronic kidney disease.
Zhang W; Liu L; Xiao X; Zhou H; Peng Z; Wang W; Huang L; Xie Y; Xu H; Tao L; Nie W; Yuan X; Liu F; Yuan Q
Front Immunol; 2023; 14():961642. PubMed ID: 37026010
[TBL] [Abstract][Full Text] [Related]
35. Gene expression profile analysis to discover molecular signatures for early diagnosis and therapies of triple-negative breast cancer.
Alam MS; Sultana A; Wang G; Haque Mollah MN
Front Mol Biosci; 2022; 9():1049741. PubMed ID: 36567949
[TBL] [Abstract][Full Text] [Related]
36. A Network-Based Analysis Reveals the Mechanism Underlying Vitamin D in Suppressing Cytokine Storm and Virus in SARS-CoV-2 Infection.
Ahmed F
Front Immunol; 2020; 11():590459. PubMed ID: 33362771
[TBL] [Abstract][Full Text] [Related]
37. Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach.
O'Donovan SM; Imami A; Eby H; Henkel ND; Creeden JF; Asah S; Zhang X; Wu X; Alnafisah R; Taylor RT; Reigle J; Thorman A; Shamsaei B; Meller J; McCullumsmith RE
Sci Rep; 2021 Feb; 11(1):4495. PubMed ID: 33627767
[TBL] [Abstract][Full Text] [Related]
38. A new insight into sex-specific non-coding RNAs and networks in response to SARS-CoV-2.
Askari N; Hadizadeh M; Rashidifar M
Infect Genet Evol; 2022 Jan; 97():105195. PubMed ID: 34954105
[TBL] [Abstract][Full Text] [Related]
39. Matrix metallopeptidase 9 as a host protein target of chloroquine and melatonin for immunoregulation in COVID-19: A network-based meta-analysis.
Hazra S; Chaudhuri AG; Tiwary BK; Chakrabarti N
Life Sci; 2020 Sep; 257():118096. PubMed ID: 32679150
[TBL] [Abstract][Full Text] [Related]
40. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
Wang ZZ; Li K; Maskey AR; Huang W; Toutov AA; Yang N; Srivastava K; Geliebter J; Tiwari R; Miao M; Li XM
FASEB J; 2021 Apr; 35(4):e21360. PubMed ID: 33749932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
